The Merck Group Website
The Merck Group Website

RebiDose™

 
RebiDose™ is a single use, pre-filled pen for the self-administration of Rebif® (interferon beta-1a), a disease-modifying drug used to treat relapsing forms of multiple sclerosis (MS). This quick and simple injection device was designed with MS patients in mind. It is a particularly convenient way to maintain therapy when traveling, for example.
This device is available in a monthly pack in two different doses (22 micrograms and 44 micrograms) and in a titration pack including two different doses (8.8 micrograms and 22 micrograms). RebiDose™ has been approved in the European Union and in Australia. It will be rolled out on a country-by-country basis, with the first launches scheduled for the end of 2010.
 
Disclaimer

The information contained in these pages is intended for general reference only. It may refer to pharmaceutical products, therapeutics or indications not yet registered or approved in a given country. This information should not be used to diagnose, treat, cure or prevent any disease without the advice of a qualified medical professional, and does not replace medical advice or a medical examination.

US Residents should consult EMD Serono, Inc. for information on products approved for sale in the United States of America.